Contact
searchSearch
HMP Global
Login

News

News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
Allison Casey
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
Promising Efficacy With Bevacizumab Plus Pembrolizumab for Platinum-Resistant Nasopharyngeal Carcinoma
01/23/2025
Stephanie Holland
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study...
01/23/2025
Oncology
News
First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/26/2024
Stephanie Holland
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the...
07/26/2024
Oncology
Conference Coverage
Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma
06/20/2024

Stephanie Holland 

Stephanie Holland 
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose...
06/20/2024
Oncology
Conference Coverage
Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma
06/20/2024

Stephanie Holland 

Stephanie Holland 
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose...
06/20/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Tisotumab Vedotin Showed Promising Clinical Activity Among Heavily Pretreated Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/11/2024

Stephanie Holland 

Stephanie Holland 
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results...
06/11/2024
Oncology
Conference Coverage
Tisotumab Vedotin Showed Promising Clinical Activity Among Heavily Pretreated Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/11/2024

Stephanie Holland 

Stephanie Holland 
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results...
06/11/2024
Oncology
News
Addition of Vismodegib to Radiation Therapy Shows Promise Among Patients With Basal Cell Carcinoma
05/10/2024

Stephanie Holland 

Stephanie Holland 
Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.
Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.
Results from a prospective,...
05/10/2024
Oncology
News
Radiotherapy Alone After Chemotherapy Induction for Patients With Nasopharyngeal Carcinoma
02/23/2024

Allison Casey

Allison Casey
According to results from a phase 3 trial, radiotherapy alone was noninferior to chemoradiotherapy following induction chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma.
According to results from a phase 3 trial, radiotherapy alone was noninferior to chemoradiotherapy following induction chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma.
According to results from a...
02/23/2024
Oncology

Recent News

News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
Stephanie Holland
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Stephanie Holland
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use